Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer.
Cheema, P K; Burkes, R L; Current Oncology, 2013, vol. 20, issue 2, p e150, ISSN 11980052. ISBN 11980052.

Full Text Resources Located for this Citation

View article on EBSCOhost(Login required)
View article via CrossRef